NDA 021748 · Santarus INC
Glumetza
Metformin Hydrochloride · Oral
DiscontinuedLast checked: Nov 19, 2026Latest source record: Aug 11, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2005
Jun 3, 2005
Approved uses
1
Original approval plus efficacy supplements
Registered trials
2,828
753 Phase 3, 150 recruiting
FAERS reports
60,186
43,694 serious, 5,792 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: LACTIC ACIDOSIS Postmarketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension, and resistant bradyarrhythmias. The onset of metformin-associated lactic acidosis is often subtle, accompanied only by nonspecific symptoms such as malaise, myalgias, respiratory distress, somnolence, and abdominal pain. Metformin-associated lactic acidosis was characterized by elevated blood lactate levels (>5 mmol/Liter), anion gap acidosis (without evidence of ketonuria or ketonemia), an increased lactate/pyruvate ratio, and metformin plasma levels generally >5 mcg/mL [see Warnings and Precautions ( 5.1 )] . Risk factors for metformin-associated lactic acidosis include renal impairment, concomitant use of certain drugs (e.g., carbonic anhydrase inhibitors such as topiramate), age 65 years old or greater, having a radiological study with contrast,...
What it is approved for
From the label in effect Sep 2, 2026.
GLUMETZA is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. GLUMETZA is a biguanide indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. (1)
Mechanism: Metformin is a biguanide that improves glucose tolerance in patients with type 2 diabetes, lowering both basal and postprandial plasma glucose. Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization. With metformin therapy, insulin secretion remains unchanged while fasting insulin levels and day-long plasma insulin response may decrease.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
2 products under this application
- GLUMETZA · METFORMIN HYDROCHLORIDE 1GM · TABLET, EXTENDED RELEASE, ORAL · Discontinued · TE AB3
- GLUMETZA · METFORMIN HYDROCHLORIDE 500MG · TABLET, EXTENDED RELEASE, ORAL · Discontinued · TE AB3
Clinical trials
Interventional ClinicalTrials.gov studies with "Metformin" as an intervention, any sponsor and status, largest first.
- Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug EfficacyPivotal-lookingActive, not recruiting
Medical Research CouncilGovernment (non-federal)
NCT00268476 · 11,992 participants · Start Jul 8, 2005 · Primary completion Mar 2026
Drug: Celecoxib; Docetaxel and 7 more · For: Prostate Cancer
Sites: Lausanne, Switzerland; Winterthur, Switzerland; Chur, Switzerland · 120 sites in all
- ACTIV-6: COVID-19 Study of Repurposed MedicationsPivotal-lookingCompleted
Susanna Naggie, MDAcademic, hospital or other
NCT04885530 · 10,956 participants · Start Jun 8, 2021 · Primary completion Apr 29, 2024
Drug: Ivermectin; Fluvoxamine and 3 more · For: Covid19
Sites: Chandler, Arizona; Gilbert, Arizona; Mesa, Arizona · 110 sites in all
- Action to Control Cardiovascular Risk in Diabetes (ACCORD)Pivotal-lookingCompleted
National Heart, Lung, and Blood Institute (NHLBI)NIH
NCT00000620 · 10,251 participants · Start Sep 1999 · Primary completion Jun 2009
Drug: Anti-hyperglycemic Agents; Anti-hypertensive Agents and 1 more · For: Atherosclerosis; Cardiovascular Diseases; Hypercholesterolemia and 4 more
Sites: Minneapolis, Minnesota; New York, New York; Winston-Salem, North Carolina · 7 sites in all
Juliana CN ChanAcademic, hospital or other
NCT06693934 · 9,000 participants (planned) · Start Nov 23, 2024 · Primary completion Oct 2027
Drug: Medication · For: Diabetes; Pre Diabetes; Hypertension and 2 more
Sites: Hong Kong, Hong Kong
- Primary Prevention of Cardiovascular Disease (CVD) in Pre-diabetic & Pre-hypertensive SubjectsPivotal-lookingStatus unknown
Ramathibodi HospitalAcademic, hospital or other
NCT01364675 · 8,900 participants (planned) · Start Jan 2012 · Primary completion Jul 2016
Drug: Metformin+Enalapril+Simvastatin; Placebo tablet · For: Pre-diabetes; Pre-hypertension
Sites: Muang District, Thailand
- Investigation of Metformin in Pre-Diabetes on Atherosclerotic Cardiovascular OuTcomesPivotal-lookingRecruiting
VA Office of Research and DevelopmentFederal agency
NCT02915198 · 7,410 participants (planned) · Start Apr 3, 2023 · Primary completion Sep 28, 2029
Drug: Metformin XR; Placebo · For: Prediabetic State; Atherosclerosis; Metformin
Sites: Phoenix, Arizona; Tucson, Arizona; Little Rock, Arkansas · 40 sites in all
- A Registry-based Randomized Controlled Trial in Type 2 Diabetes With Cardiovascular Risk Factors (REMATCH)Pivotal-lookingRecruiting
Kyu Chang WonAcademic, hospital or other
NCT06627322 · 5,950 participants (planned) · Start Nov 21, 2024 · Primary completion Sep 30, 2029
Drug: Dual-combination therapy; Triple-combination therapy · For: Type 2 Diabetes
Sites: Daegu, South Korea; Seoul, South Korea
- A Study of the Safety and Efficacy of Glimepiride, Gliclazide, Repaglinide or Acarbose When Added to Sitagliptin + Metformin Combination Therapy in Chinese Participants With Diabetes (MK-0431-313)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT01709305 · 5,570 participants · Start Nov 8, 2012 · Primary completion Apr 17, 2015
Drug: Metformin; Sitagliptin and 4 more · For: Type 2 Diabetes Mellitus
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- lactic acidosis4,572
- diarrhoea4,532
- nausea3,677
- acute kidney injury3,336
- fatigue3,257
- drug ineffective2,883
- vomiting2,741
- dyspnoea2,732
- headache2,423
- off label use2,267
- dizziness2,240
- asthenia2,181
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 94 |
| 2005 | 133 |
| 2006 | 408 |
| 2007 | 284 |
| 2008 | 441 |
| 2009 | 676 |
| 2010 | 984 |
| 2011 | 950 |
| 2012 | 1,968 |
| 2013 | 896 |
| 2014 | 967 |
| 2015 | 1,954 |
| 2016 | 2,273 |
| 2017 | 2,672 |
| 2018 | 3,943 |
| 2019 | 3,228 |
| 2020 | 2,817 |
| 2021 | 3,533 |
| 2022 | 6,432 |
| 2023 | 6,369 |
| 2024 | 6,922 |
| 2025 | 7,079 |
| 2026 | 5,161 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Glumetza (Metformin HCl)
2024 spending
$19.8M
Beneficiaries
1,014
3,112 claims
Per beneficiary
$19,533
$73.01 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $44,928,543 |
| 2021 | $44,842,796 |
| 2022 | $39,094,409 |
| 2023 | $37,772,978 |
| 2024 | $19,806,298 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Inositol is an effective and safe treatment in polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials.
Greff D, Juhász AE, Váncsa S, et al. · Reprod Biol Endocrinol 2023 · Meta-Analysis, Systematic Review
- Metformin and Combined Oral Contraceptive Pills in the Management of Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis.
Melin J, Forslund M, Alesi S, et al. · J Clin Endocrinol Metab 2024 · Meta-Analysis, Systematic Review
- GLP-1 receptor agonists versus metformin in PCOS: a systematic review and meta-analysis.
Han Y, Li Y, He B · Reprod Biomed Online 2019 · Comparative Study, Meta-Analysis
- Comparative Effectiveness of Glucose-Lowering Drugs for Type 2 Diabetes: A Systematic Review and Network Meta-analysis.
Tsapas A, Avgerinos I, Karagiannis T, et al. · Ann Intern Med 2020 · Comparative Study, Research Support, Non-U.S. Gov't
- The impact of metformin with or without lifestyle modification versus placebo on polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials.
Melin J, Forslund M, Alesi S, et al. · Eur J Endocrinol 2023 · Meta-Analysis, Systematic Review
- Gastrointestinal adverse events of metformin treatment in patients with type 2 diabetes mellitus: A systematic review, meta-analysis and meta-regression of randomized controlled trials.
Nabrdalik K, Skonieczna-Żydecka K, Irlik K, et al. · Front Endocrinol (Lausanne) 2022 · Meta-Analysis, Systematic Review
Sponsor: Santarus INC
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.